Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-15-003747
Filing Date
2015-11-16
Accepted
2015-11-16 16:20:01
Documents
11
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q fpmi10q_sep302015.htm 10-Q 596232
2 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-1.htm EX-31.1 16510
3 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-2.htm EX-31.2 16631
4 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-1.htm EX-32.1 5715
5 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-2.htm EX-32.2 5841
  Complete submission text file 0001415889-15-003747.txt   2825990

Data Files

Seq Description Document Type Size
6 fpmi-20150930.xml EX-101.INS 392547
7 fpmi-20150930.xsd EX-101.SCH 30656
8 fpmi-20150930_cal.xml EX-101.CAL 39215
9 fpmi-20150930_def.xml EX-101.DEF 117003
10 fpmi-20150930_lab.xml EX-101.LAB 235184
11 fpmi-20150930_pre.xml EX-101.PRE 194150
Mailing Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042
Business Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042 973-744-1565
FLUOROPHARMA MEDICAL, INC. (Filer) CIK: 0001402785 (see all company filings)

EIN.: 208325616 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-147193 | Film No.: 151234784
SIC: 2835 In Vitro & In Vivo Diagnostic Substances